Ads
related to: cyberknife radiation and lung cancer risk factors chart
Search results
Results From The WOW.Com Content Network
The inaugural CyberKnife system was installed at Stanford University in 1991, receiving clearance for clinical investigation by the U.S. Food and Drug Administration (FDA) in 1994. Following extensive clinical research , the FDA granted approval for the treatment of intracranial tumors in 1999 and for tumors throughout the body in 2001.
Lung cancer susceptibility tests suggest the probability or susceptibility an individual may have of getting lung cancer. Lung cancer is a disease characterized by uncontrolled cell growth in the lung tissue. If left untreated, this growth can spread beyond the lungs in a process called metastasis, into nearby tissues or other parts of the body.
Oklahoma CyberKnife is a cancer treatment center based in Oklahoma. The center treats malignant and benign tumors in the lungs, spine, brain, liver, pancreas, eye, prostate and kidney using CyberKnife technology. Oklahoma CyberKnife has treated patients from around Oklahoma as well as patients from bordering states.
Radiation hormesis is the conjecture that a low level of ionizing radiation (i.e., near the level of Earth's natural background radiation) helps "immunize" cells against DNA damage from other causes (such as free radicals or larger doses of ionizing radiation), and decreases the risk of cancer. The theory proposes that such low levels activate ...
This is done using tissue weighting factor, which takes into account how each tissue in the body has different sensitivity to radiation. [4] The effective dose is the risk of radiation averaged over the entire body. [4] Ionizing radiation is known to cause cancer in humans. [4]
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. [1] [2] [3] As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma.